| 2026-08-06 | Press release | ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-06-30 | Press release | ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules |
| 2026-06-30 | Press release | ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel |
| 2026-05-08 | Press release | ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-05-07 | Earnings deck | Presentation |
| 2026-05-07 | Press release | ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advance |
| 2026-05-07 | Presentation | ALX Oncology Corporate Presentation May 8 2026 |
| 2026-04-30 | Press release | ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in A |
| 2026-04-17 | Press release | ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules |
| 2026-04-13 | Press release | ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer |
| 2026-02-27 | Press release | ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update |
| 2026-01-12 | Presentation | ALX presentation at JPM 2026 _12Jan2026_FINAL.pdf |
| Press release | ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
| Press release | Read more |
| Press release | ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
| Press release | Read more |
| Press release | ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update |
| Press release | Read more |
| Press release | ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update |
| Press release | Read more |
| Press release | ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
| Press release | ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update |
| Press release | ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update |
| Press release | Read more |
| Press release | ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update |
| Press release | ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update |
| Press release | ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights |
| Press release | ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operation |
| Press release | ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights |
| Press release | ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights |
| Press release | ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights |
| Press release | Read more |
| Press release | ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights |
| Press release | ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights |
| Press release | ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights |
| Press release | ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights |
| Press release | ALX Oncology Reports Second Quarter 2020 Financial Results and Provides Operational and Clinical Highlights |